it seems like the FDA is suddenly including cost of a drug in it s approval process. I saw something on google where the FDA is apparently saying the the cost of the drug is now too much given its benefits for breast cancer treatment. The FDA has never before allowed cost to be a factor - only clinical effectiveness. It seems that they said it had to show at least a 5 month improvement to be worthwhile given the cost! The average improvement was only 3 months.
Since when is adding 3 months on average to your life if you have breast cancer not valuable enough? Is this the beginning of "bending the cost curve" that we hear so much about?
Very few articles are mentioning this but it seems the cost factor was in the FDA statement cancelling approval for avatin.
Can you help?
All user-generated information on this site is the opinion of its author only and is not a substitute for medical advice or treatment for any medical conditions. Members and guests are responsible for their own posts and the potential consequences of those posts detailed in our Terms of Service.